Background/Objectives: Pancreatic adenocarcinoma (PAC) is a disease with a poor prognosis. Hepatitis B (HBV)/Hepatitis C (HCV) viruses are hepatotropic pathogens with pro-carcinogenic properties able to attack also the pancreas. Although several trials, mainly carried out in the USA and in the Eastern Countries, strongly suggested that HBV/HCV exert a role in PAC development, no study on this topic was still performed in Italy. Through this present work, we aimed to assess HBV antigens/antibodies and anti-HCV antibodies prevalence in a small cohort of Italian patients with PAC, irrespective of the other risk factors for PAC development, like smoking, alcohol drinking, and diabetes. Methods: This pivotal-retrospective-study was led both at Surgery Unit of Maggiore Hospital, (Bologna) and at Unit of Gastroenterology and Digestive Endoscopy of Sandro Pertini Hospital, (Rome). Data concerning age, sex, pancreatic cancer localization (head, body, tail) and serum HBV/HCV profiles of subjects with a histological/radiological/biochemical diagnosis of PAC were collected from files concerning pancreatectomy and endoscopicretrograde-cholangiopancreatography (ERCPs).
Introduction
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human malignancy entailing a very dismal prognosis [1] , with about 459,000 cases and 432,000 deaths worldwide in 2018, according to the Global cancer statistics estimates [2] . Despite the improvement in the understanding of molecular mechanisms and events involved in the development of this neoplasm, the overall five-year survival is < 5%. Therefore, this neoplasm ranks as the 14th most common malignancy and the 7th highest cause of tumor-related mortality in the world. The poor prognosis of PAC depends on several factors, such as its aggressive biological behavior, its early ability to spread locally as well as to metastasize at distance and its asymptomatic course in the initial stages of carcinogenesis [3] . Despite several efforts in the past and even in the last times, the diagnosis of this cancer is very often performed at an advanced stage, when the available therapeutic options, both surgical and pharmacological ones, are ineffective or useless. At the time of diagnosis, most PACs have already disseminated beyond the pancreas [4, 5] and recurrence rates of this tumor are very high (about 85%), even if a curative resection is performed [6] .
Only a few risk factors are known to be associated with its development, including smoking, chronic pancreatitis, familial cancer syndromes, diabetes and alcohol [7] . Since a substantial enhancement in PAC incidence was progressively observed over recent years and it is still expected to increase in the next decades, at least in the most developed Countries for several reasons [8] , the identification of modifiable or treatable risk factors of this severe and lethal disease has become a pressing need [9] . An approach intended to the development of screening programs, targeted at highrisk people for prevention or early detection of PAC is strongly required, like this strategy, if adopted, could contribute to increase survival rates and improve the quality of life of people suffering from this pathology.
In our clinical and scientific study, we mean to evaluate the possible factors associated with pancreatic carcinogenesis. As multiple pieces of evidence from epidemiological and basic research studies suggest that about 15-20% of all malignancies are somehow linked to a viral infection [10] , in the last years we have turned our attention to investigate the potential role of Hepatitis B (HBV) and C (HCV) viruses in PAC development.
These hepatotropic pathogens own well-known carcinogenic properties for the liver, but their antigens and genomes may be detected also in extra-hepatic tissues, including the pancreas. HBV antigens and genome, as well as intermediate HCV genome replication forms, have been found in exocrine and endocrine pancreatic cells [11] [12] [13] . Taking advantage of these evidence, in the last years, some studies have been carried out with the aim to investigate the possible mechanisms involved in the processes of pancreatic carcinogenesis. Several reports have shown the possible intra-and extra-cellular targets of some viral proteins,
including Hepatitis x protein (HBx) for HBV, nonstructural 3 (NS3), 4 A (NS4A), 5A (NS5A) and 5B (NS5B) for HCV. Most of these binding sites have been shown in animal and human cell culture systems derived mainly from hepatocytes or hepatoma cell lines, but also from pancreatic cancer cells [14] . HBx, NS3, NS5A and NS5B have been demonstrated to dysregulate the expression profile of some cellular cytoskeletal genes [15] or to interact with distinct elements of cytoskeleton (microfilaments, microtubules, intermediate filaments and actin stress fibers) [16] [17] [18] [19] , proto-oncogene tyrosine-protein kinase Src (Src-) [20] and Focal adhesion tyrosinekinase (FAK)-pathways [21] [22] [23] [24] and of cell to cell and cell to extracellular-matrix adhesion molecules [25] , such as Integrins [26, 27] , E-Cadherin, β-catenin [28] and CD 44 [29, 30] . In addition, it has reported that HBx may directly modulate the activities of a lot of nuclear transcription factors, influencing their function.
These events lead to a perturbation of cell and stroma composition as well as of their structure, shape, disposition and of their physical-and chemicalproperties [31] [32] [33] [34] . This complex series of modification induces deep deregulation of normal cell and extracellular matrix function and promotes the malignant transformation of the cells and of the matrix surrounding them. Some of these events are described in In particular, based on these criteria, we obtained the following results:
1. concerning HBV infection and risk of PAC development, we identified 6 case-controls (in USA [36] , Taiwan [37] , Korea [38] and China [39] [40] [41] ), 9 cohort studies (in Taiwan [42, 43] , USA [44, 45] , Australia [46, 47] , Sweden [48] , Denmark [49] and Japan [50] ) and 7 metaanalysis (in China [51] [52] [53] [54] [55] , USA [56] and Italy [35] ). Most of case-controls, cohort trials and all meta-analyses registered an increased risk of PAC development;
2. as regards HCV infection, 4 case-controls (in China [41] , USA [36] , Korea [38] and Taiwan [37] ), 7 cohort studies (in USA [57, 58] , Australia [46, 47] , Denmark [59] , Sweden [48] and Japan [50] ) and 3 meta-analyses (in China [54, 55] 
Material and methods

Study Population
In this pivotal bi-Centre retrospective study we , 1975-1984, 1965-1974, 1955-1964, 1945-1954, 1935-1944 , <1935. Then we summarized our results in some synthetic tables, together with data on the prevalence of HBsAg, HBsAb/HBcAb and anti-HCV.
Continuous variables were expressed as mean ± standard deviation and compared to two sample t-test; categorical data were indicated as numbers (percentages) and p-value less than 0.05 was significant.
Results
The distribution of demographic characteristics and the selected variables of the patients analyzed are reported in Table 2 . Merging the two results arising from the two groups, the overall mean age was 68.2 ±10.1 years.
HBV markers prevalence
In our study population, four patients turned out to be HBsAg positive, with a prevalence equal to 1% in 373 patients. In the overall Italian population, the available surveys report similar values. In 28 individuals we observed the coexistence of HBsAb and HBcAb in their serum. The prevalence of HBsAb/HBcAb was equal to 7.5% in 373 subjects (Tables 3 and 4 ). 
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HCV markers prevalence
Sixteen patients were HCV positive, with a prevalence in our study population equal to 4.3%. The prevalence of anti-HCV positivity in our study population was variable, depending on the different age -as well as birthclasses, as also reported in trials by Andriulli and
Fabris (Table 5) . Table 5 and (such as matricellular proteins), emerges. One of the most important effects of these complex processes is the increase of the tissue stiffness, a well-known factor promoting carcinogenesis (see Table 6 and Figure 1 HBV infection in PAC development [74, 75] . In several countries with decreased HBsAg prevalence, such as
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Italy, owing to long-term vaccination programs a significant number of subjects with markers of past exposure to HBV (serum HBsAb and/or HBcAb positivity) persists and these individuals might present a higher risk of PDAC [76] .
Unfortunately, only a small number of trials have been carried out with the aim to understand this important point and the results are not univocal.
In particular, in the past two case-control studies detected an increased risk of PDAC in HBsAg-/HBcAb+/HBsAb-individuals [36, 39] , whereas one study did not do it [40] . On the other hand, concerning
HBsAg-/HBcAb+/HBsAb+ profile, two case-control studies showed an enhanced probability to develop this malignancy [36, 40] whereas one study did not do it [39] . The recent large sized cohort studies in the USA provided no specific contribution to clarify this important matter of debate. However, two metaanalyses, including these studies, have argued that a significantly increased risk occurs in HBcAb+/HBsAb+ vs HBsAg-/HBcAb-individuals, with RR equals to 1.41 (95% CI: 1.06-1.87) [35, 54] and in HBcAb+/HBsAb-vs HBsAg-/HBcAb-subjects, with OR equals to 1.76 (95% CI: 1.05-2.93). In any case, further studies are necessary. 
